Showing results (11-20 of 18) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Journal for Immunotherapy of Cancer|June 29, 2026
Lenalidomide boosts CD1d-Vδ2 bispecific antibody-engaged Vγ9Vδ2-T cell effector functions via CD28, Notch signaling and IL-2 releaseMilon de Jong, Myrthe Veth, Tereza Brachtlová, et al.Clinical Immunology (Orlando, Fla.)|April 18, 2026
A trophoblast glycoprotein specific 5 T4-Vδ2 bispecific T cell engager recruits Vγ9Vδ2-T cells for tumor-selective cytotoxicity across solid malignanciesMilon de Jong, Rok Žiberna, Myrthe Veth, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2021
A Bispecific Single-Domain Antibody Boosts Autologous Vγ9Vδ2-T Cell Responses Toward CD1d in Chronic Lymphocytic LeukemiaIris de Weerdt, Roeland Lameris, Jurjen M Ruben, et al.Cancer Immunology Research|November 12, 2020
A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell-Mediated Antitumor Responses in Human B-cell MalignanciesIris de Weerdt, Roeland Lameris, George L Scheffer, et al.Nature Cancer|February 5, 2022
A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent antitumor responseRoeland Lameris, Adam Shahine, Daniel G Pellicci, et al.Cell Reports. Medicine|March 3, 2023
A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignanciesRoeland Lameris, Jurjen M Ruben, Victoria Iglesias-Guimarais, et al.Blood|September 15, 2018
Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinibIris de Weerdt, Tom Hofland, Roeland Lameris, et al.Oncoimmunology|January 4, 2018
A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cellsRenée C G de Bruin, John P Veluchamy, Sinéad M Lougheed, et al.Pageof 2